International Journal of Oral Biology

The Korean Academy of Oral Biology (대한구강생물학회)
권호 표지
DOI QR코드

DOI QR Code

The Regulatory Effects of Trans-chalcone on Adipogenesis

  • Han, Younho (Department of Oral Pharmacology, College of Dentistry, Wonkwang University)
  • Received : 2018.02.02
  • Accepted : 2018.03.04
  • Published : 2018.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

It is noted that chalcone derivatives have characteristic diverse pharmacological properties, and that precise evidence has been growing that they could regulate a tumor necrosis $factor-{\alpha}$ ($TNF-{\alpha}$) induced insulin resistance. The purpose of the present investigation is to elucidate the effects of the identified chalcone derivatives on adipogenesis, and to find the underlying mechanism of action in that case. Consequently, we first investigated whether the chalcone derivatives could affect the identified $PPAR{\gamma}$-induced transcriptional activity on the proliferator-activated receptor response elements (PPRE) at target promoters, and find that trans-chalcone most significantly increased the $PPAR{\gamma}$-induced transcriptional activity. Additionally, we confirmed that there were up-regulatory effects of trans-chalcone during the adipogenesis and lipid accumulation, and on the mRNA of adipogenic factors in 3T3-L1 cells. Next, we examined the effect of trans-chalcone on the inhibition induced by $TNF-{\alpha}$ on adipogenesis. To that end, we noted that the treatment with trans-chalcone attenuated the effect of $TNF-{\alpha}$ mediated secretion of various adipokines that are involved in insulin sensitivity. For this reason, we noted that this study clearly demonstrates that trans-chalcone enhanced adipogenesis, in part, by its potent effect on $PPAR{\gamma}$ activation and by its reverse effect on $TNF-{\alpha}$.

Keywords

References

  1. Ju, Z.G., C.L. Liu, and Y.B. Yuan, Activities of Chalcone Synthase and Udpgal - Flavonoid-3-O-Glycosyltransferase in Relation to Anthocyanin Synthesis in Apple. Scientia Horticulturae, 1995;63(3-4):175-185. https://doi.org/10.1016/0304-4238(95)00807-6
  2. Orlikova, B., et al., Dietary chalcones with chemopreventive and chemotherapeutic potential. Genes Nutr, 2011;6(2): 125-47. https://doi.org/10.1007/s12263-011-0210-5
  3. Lin, Y.M., et al., Chalcones and flavonoids as anti- tuberculosis agents. Bioorg Med Chem, 2002;10(8):2795-802. https://doi.org/10.1016/S0968-0896(02)00094-9
  4. Fogaca, T.B., et al., Apoptotic effect of chalcone derivatives of 2-acetylthiophene in human breast cancer cells. Pharmacological Reports, 2017;69(1):156-161. https://doi.org/10.1016/j.pharep.2016.10.003
  5. Nowakowska, Z., A review of anti-infective and antiinflammatory chalcones. Eur J Med Chem, 2007;42(2): 125-37. https://doi.org/10.1016/j.ejmech.2006.09.019
  6. Yadav, V.R., et al., The role of chalcones in suppression of NF-kappaB-mediated inflammation and cancer. Int Immunopharmacol, 2011;11(3):295-309. https://doi.org/10.1016/j.intimp.2010.12.006
  7. Kamei, H., et al., Tumor cell growth suppression by chalcone (1,3-diphenyl-2-propen-1-one). Cancer Biotherapy and Radiopharmaceuticals, 1997;12(1):51-54. https://doi.org/10.1089/cbr.1997.12.51
  8. Kotronen, A., et al., Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Gastroenterology, 2008;135(1):122-30. https://doi.org/10.1053/j.gastro.2008.03.021
  9. Wallia, A. and M.E. Molitch, Insulin Therapy for Type 2 Diabetes Mellitus. Jama-Journal of the American Medical Association, 2014;311(22):2315-2325. https://doi.org/10.1001/jama.2014.5951
  10. Aberer, F., et al., Review of the Efficiency and Safety of a simple Insulin Dispensing Device (PaQ (R)) in Patients with Diabetes mellitus Type 2. Wiener Klinische Wochenschrift, 2015;127:S136-S136.
  11. Andrade-Oliveira, V., N.O. Camara, and P.M. Moraes-Vieira, Adipokines as drug targets in diabetes and underlying disturbances. J Diabetes Res, 2015;2015:681612.
  12. Kim, S.G., et al., Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with prediabetes or non-diabetic metabolic syndrome. Eur J Endocrinol, 2006;154(3):433-40. https://doi.org/10.1530/eje.1.02100
  13. Buras, J., et al., Troglitazone-induced changes in adiponectin do not affect endothelial function in diabetes. Obes Res, 2005;13(7):1167-74. https://doi.org/10.1038/oby.2005.138
  14. Rasouli, N., et al., Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. American Journal of Physiology-Endocrinology and Metabolism, 2006;290(1): E42-E46. https://doi.org/10.1152/ajpendo.00240.2005
  15. Roughead, E.E., et al., Variation in Association Between Thiazolidinediones and Heart Failure Across Ethnic Groups: Retrospective analysis of Large Healthcare Claims Databases in Six Countries. Drug Saf, 2015;38(9):823-31. https://doi.org/10.1007/s40264-015-0318-4
  16. Govindan, J. and M. Evans, Pioglitazone in clinical practice: where are we now? Diabetes Ther, 2012;3(1):1-8. https://doi.org/10.1007/s13300-012-0001-z
  17. Hsieh, C.T., et al., Synthesis of chalcone derivatives as potential anti-diabetic agents. Bioorganic & Medicinal Chemistry Letters, 2012;22(12):3912-3915. https://doi.org/10.1016/j.bmcl.2012.04.108
  18. Spiegelman, B.M., PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes, 1998;47(4):507-14. https://doi.org/10.2337/diabetes.47.4.507
  19. Swaroop, J.J., D. Rajarajeswari, and J.N. Naidu, Association of TNF-alpha with insulin resistance in type 2 diabetes mellitus. Indian J Med Res, 2012;135:127-30. https://doi.org/10.4103/0971-5916.93435
  20. Jain, R.G., K.D. Phelps, and P.H. Pekala, Tumor necrosis factor-alpha initiated signal transduction in 3T3-L1 adipocytes. J Cell Physiol, 1999; 179(1):58-66. https://doi.org/10.1002/(SICI)1097-4652(199904)179:1<58::AID-JCP8>3.0.CO;2-1
  21. Ohnogi, H., et al., Six New Chalcones from Angelica keiskei Inducing Adiponectin Production in 3T3-L1 Adipocytes. Bioscience Biotechnology and Biochemistry, 2012;76(5): 961-966. https://doi.org/10.1271/bbb.110976
  22. Lee da, Y., et al., A synthetic chalcone derivative, 2-hydroxy- 3',5,5'-trimethoxychalcone (DK-139), suppresses the TNF alpha-induced invasive capability of MDA-MB-231 human breast cancer cells by inhibiting NF-kappaB-mediated GRO alpha expression. Bioorg Med Chem Lett, 2016;26(1):203-8. https://doi.org/10.1016/j.bmcl.2015.10.094
  23. Meng, C.Q., et al., Discovery of novel heteroaryl-substituted chalcones as inhibitors of TNF-alpha-induced VCAM-1 expression. Bioorg Med Chem Lett, 2004;14(6):1513-7. https://doi.org/10.1016/j.bmcl.2004.01.021
  24. Zou, C. and J. Shao, Role of adipocytokines in obesityassociated insulin resistance. J Nutr Biochem, 2008;19(5): 277-86. https://doi.org/10.1016/j.jnutbio.2007.06.006
  25. Ferre, P., The biology of peroxisome proliferator - Activated receptors - Relationship with lipid metabolism and insulin sensitivity. Diabetes, 2004;53:S43-S50. https://doi.org/10.2337/diabetes.53.2007.S43
  26. Iwaki, M., et al., Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes, 2003;52(7):1655-63. https://doi.org/10.2337/diabetes.52.7.1655
  27. Sethi, J.K. and G.S. Hotamisligil, The role of TNF alpha in adipocyte metabolism. Seminars in Cell & Developmental Biology, 1999;10(1):19-29. https://doi.org/10.1006/scdb.1998.0273
  28. Hotamisligil, G.S., N.S. Shargill, and B.M. Spiegelman, Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science, 1993; 259(5091):87-91. https://doi.org/10.1126/science.7678183
  29. Pandey, M., D.J. Loskutoff, and F. Samad, Molecular mechanisms of tumor necrosis factor-alpha-mediated plasminogen activator inhibitor-1 expression in adipocytes. Faseb Journal, 2005;19(7):1317-+. https://doi.org/10.1096/fj.04-3459fje